These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 20022854

  • 1. [New drugs in metastatic castration-resistant prostate cancer].
    Albiges L, Loriot Y, Gross-Goupil M, de La Motte Rouge T, Blesius A, Escudier B, Massard C, Fizazi K.
    Bull Cancer; 2010 Jan; 97(1):149-59. PubMed ID: 20022854
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Novel and bone-targeted agents for CRPC.
    Fizazi K, Albiges L, Massard C, Escudier B, Loriot Y.
    Ann Oncol; 2012 Sep; 23 Suppl 10():x264-7. PubMed ID: 22987974
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Agents that target androgen synthesis in castration-resistant prostate cancer.
    Ferraldeschi R, de Bono J.
    Cancer J; 2013 Sep; 19(1):34-42. PubMed ID: 23337755
    [Abstract] [Full Text] [Related]

  • 6. New treatment options for patients with metastatic castration-resistant prostate cancer.
    Higano CS.
    Cancer Treat Rev; 2012 Aug; 38(5):340-5. PubMed ID: 21944872
    [Abstract] [Full Text] [Related]

  • 7. Emerging treatments for castrate-resistant prostate cancer.
    Redding MB, Surati M.
    J Pharm Pract; 2011 Aug; 24(4):366-73. PubMed ID: 21984773
    [Abstract] [Full Text] [Related]

  • 8. Contemporary management of metastatic castration-resistant prostate cancer.
    Sonpavde G, Sternberg CN.
    Curr Opin Urol; 2011 May; 21(3):241-7. PubMed ID: 21455038
    [Abstract] [Full Text] [Related]

  • 9. [Strategy in advanced castration-resistant prostate cancer].
    Gross-Goupil M, Roca S, Pasticier G, Ravaud A.
    Bull Cancer; 2012 Jul; 99 Suppl 1():S37-45. PubMed ID: 22522582
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunities.
    Payne H, Bahl A, Mason M, Troup J, De Bono J.
    BJU Int; 2012 Sep; 110(5):658-67. PubMed ID: 22429837
    [Abstract] [Full Text] [Related]

  • 12. [Castration resistant prostate cancer 2011].
    Miller K.
    Aktuelle Urol; 2011 Mar; 42(2):95-102. PubMed ID: 21437832
    [Abstract] [Full Text] [Related]

  • 13. Emerging therapies in metastatic castration-sensitive and castration-resistant prostate cancer.
    MacVicar GR, Hussain MH.
    Curr Opin Oncol; 2013 May; 25(3):252-60. PubMed ID: 23511665
    [Abstract] [Full Text] [Related]

  • 14. New therapies for castration-resistant prostate cancer: efficacy and safety.
    Beltran H, Beer TM, Carducci MA, de Bono J, Gleave M, Hussain M, Kelly WK, Saad F, Sternberg C, Tagawa ST, Tannock IF.
    Eur Urol; 2011 Aug; 60(2):279-90. PubMed ID: 21592649
    [Abstract] [Full Text] [Related]

  • 15. New developments in castrate-resistant prostate cancer.
    Shore N, Mason M, de Reijke TM.
    BJU Int; 2012 Jun; 109 Suppl 6():22-32. PubMed ID: 22672122
    [Abstract] [Full Text] [Related]

  • 16. Novel therapies for metastatic castrate-resistant prostate cancer.
    Dayyani F, Gallick GE, Logothetis CJ, Corn PG.
    J Natl Cancer Inst; 2011 Nov 16; 103(22):1665-75. PubMed ID: 21917607
    [Abstract] [Full Text] [Related]

  • 17. Abiraterone acetate, a novel adrenal inhibitor in metastatic castration-resistant prostate cancer.
    Salem M, Garcia JA.
    Curr Oncol Rep; 2011 Apr 16; 13(2):92-6. PubMed ID: 21243537
    [Abstract] [Full Text] [Related]

  • 18. Novel therapeutics for the management of castration-resistant prostate cancer (CRPC).
    Lee DJ, Cha EK, Dubin JM, Beltran H, Chromecki TF, Fajkovic H, Scherr DS, Tagawa ST, Shariat SF.
    BJU Int; 2012 Apr 16; 109(7):968-85. PubMed ID: 22035221
    [Abstract] [Full Text] [Related]

  • 19. Novel strategies in the treatment of castration-resistant prostate cancer (Review).
    Marech I, Vacca A, Ranieri G, Gnoni A, Dammacco F.
    Int J Oncol; 2012 May 16; 40(5):1313-20. PubMed ID: 22322981
    [Abstract] [Full Text] [Related]

  • 20. [Novel agents for the therapy of castration-resistant prostate cancer: overview of pivotal studies and new strategies to come].
    Ouzaid I, Ravery V, Pouessel D, Culine S.
    Prog Urol; 2013 Jan 16; 23(1):1-7. PubMed ID: 23287477
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.